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MUC4 is highly expressed in human pancreatic tumours and pancreatic tumour cell lines, but is minimally or not expressed in normal
pancreas or chronic pancreatitis. Here, we investigated the aberrant regulation of MUC4 expression in vivo using clonal human
pancreatic tumour cells (CD18/HPAF) grown either orthotopically in the pancreas (OT) or ectopically in subcutaneous tissue (SC) in
the nude mice. Histological examination of the OT and SC tumours showed moderately differentiated and anaplastic morphology,
respectively. The OT tumour cells showed metastases to distant lymph nodes and faster tumour growth (Po0.01) compared to the
SC tumours. The MUC4 transcripts in OT tumours were very high compared to the undetectable levels in SC tumours. The SC
tumour cells regained their ability to express MUC4 transcripts after in vitro culture. Immunohistochemical analysis using MUC4-
specific polyclonal antiserum confirmed the results obtained by Northern blot analysis. Interestingly, the OT tumours showed
expression of TGFb2 compared to no expression in SC, suggesting a possible link between MUC4 and TGFb2. The MUC4 expression,
morphology, and metastasis of human pancreatic tumour cells are regulated by a local host microenvironment. TGFb2 may serve as
an interim regulator of this function.
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Pancreatic adenocarcinomas are frequently associated with an
altered synthesis of mucins (Balague et al, 1994; Hollingsworth
et al, 1994; Kim et al, 1999; Andrianifahanana et al, 2001).
Biochemically, mucins are high-molecular-weight glycoproteins
and their polypeptide chains have domains rich in threonine and/
or serine, whose hydroxyl groups are in O-glycosidic linkage with
oligosaccharides. These domains are composed of tandemly
repeated sequences that vary in number, length, and amino-acid
sequence from one mucin to another (Gendler and Spicer, 1995;
Moniaux et al, 2001). They are produced mainly by the secretory
epithelial cells for the lubrication and protection of ducts and
lumen within the human body (Gendler and Spicer, 1995). In all,
14 human mucin genes have been identified, designated as MUC1-
4, MUC5B, MUC5AC, MUC6-8, MUC11-12, MUC13, and MUC16-17
(Gendler et al, 1990; Lan et al, 1990; Aubert et al, 1991; Porchet
et al, 1991; Bobek et al, 1993; Dufosse et al, 1993; Gum et al, 1994,
1997; Shankar et al, 1997; Toribara et al, 1997; Williams et al, 1999,
2001; Yin and Lloyd, 2001; Gum Jr et al, 2002). Based on the
structure, mucins are categorised into three distinct forms:
membrane spanning (MUC1, MUC3, MUC4, MUC12 and
MUC17), gel forming (MUC2, MUC5AC, MUC5B and MUC6),
and soluble (MUC7) (Moniaux et al, 2001). MUC4 has been cloned
from the human trachea and human pancreatic tumours, and the
full-length cDNA sequence is known (Nollet et al, 1998; Moniaux
et al, 1999; Choudhury et al, 2000a). The NH2-terminus of MUC4 is
composed of a 27-residue signal peptide and a large domain
varying in length from 3285–7285 amino-acid residues as a result
of variable number of 16 amino-acid tandem repeat units (VNTR).
The COOH-terminus of MUC4 encodes 12 distinct domains that
include two cysteine-rich domains, three epidermal growth factor
(EGF)-like domains, two regions rich in potential N-glycosylation
sites, one hydrophobic transmembrane region, and one short
cytoplasmic tail. Nine out of 12 of the C-terminal domains share
60–80% similarity in sequence with the rat sialomucin complex,
known as SMC. Sialomucin complex is the rat homologue of
human MUC4 and is now known as rat Muc4 (Moniaux et al,
1999).
The apomucins MUC1, MUC5B, MUC5AC, and MUC6 are
expressed in the normal pancreas; MUC1, MUC2, and MUC4 are
upregulated in pancreatic tumours (Andrianifahanana et al, 2001),
whereas MUC5B, MUC5AC, and MUC6 are slightly downregulated.
The MUC4 mucin is expressed at high levels in human pancreatic
tumours and tumour cell lines, with an undetectable level in the
normal pancreas (Andrianifahanana et al, 2001). MUC4 is also
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yexpressed by metaplastic ducts and its expression increases with
higher grade in pancreatic intraepithelial neoplasias (PanINs)
(Swart et al, 2002). The human tissues showing an undetectable
level of MUC4 expression are the gall bladder biliary epithelial
cells, intrahepatic bile ducts, and the liver (Vandenhaute et al,
1997). In contrast, the MUC4 apomucin is expressed in numerous
normal human tissues like the stomach, ovary, salivary gland,
colon, lung, trachea, uterus, and prostate (Audie et al, 1993; Reid
and Harris, 1998; Buisine et al, 1999; Gipson et al, 1999). During
foetal development, there is a complex spatiotemporal regulation
of the MUC4 gene in the gastroduodenal tract and accessory
digestive glands.
The membrane-associated mucins rat Muc4 and MUC1 have
been reported to play a role in tumour progression and metastasis
(Gendler and Spicer, 1995; Komatsu et al, 1997, 2000; Kim et al,
1999). The implantation of human tumour cells in the pancreas of
nude mice (orthotopic (OT) implantation) has proved to be useful
in studying the progression of pancreatic cancer in vivo
(Marincola et al, 1989). The organ microenvironment has been
shown to influence the physiological properties of the tumour cells
in the production of degradative enzymes and the regulation of
mdr1 mRNA and P-glycoprotein expression (Fidler et al, 1994).
The survival and growth of a particular tumour cell are
significantly affected by the local milieu provided by a particular
organ environment (Fidler et al, 1994).
In the present study, the influence of the local host micro-
environment on the expression of the MUC4 transcript and protein
was examined for the first time. Using human pancreatic
adenocarcinoma cell lines, CD18/HPAF and SW1990, human
pancreatic tumour xenografts were developed at the OT and
subcutaneous (SC) sites of the nude mouse. The morphologically
differentiated invasive OT tumours demonstrated a high level of
expression of MUC4 mRNA and protein compared to undetectable
levels in poorly differentiated SC tumours. However, the in vitro
culture of SC tumour cells resulted in the expression of MUC4
transcripts comparable with its expression level in the parental cell
line CD18/HPAF. Paracrine stimulation by growth factors and
cytokines has been demonstrated to be one of the mechanisms
responsible for the organ preference and proliferation of the
tumour cells. The MUC4-expressing OT tumours also showed
transforming growth factor (TGF)b2 expression. The study
suggests that the site of pancreatic tumour growth in vivo strongly
influences MUC4 and TGFb2 expression, tumour morphology, and
invasiveness of CD18/HPAF cells.
MATERIALS AND METHODS
Animals
Female athymic mice (nu/nu) (6–8 weeks) were obtained from
Charles River (Wilmington, MA, USA). The mice were housed in
laminar flow cabinets under specific pathogen-free conditions. The
University of Nebraska Medical Center Institutional Animal Care
and Use Committee approved animal protocols used in this study
(IACUC #97-069-03), which comply with the Public Health Service
Policy on the Humane Care and Use of Laboratory Animals.
Tumour cell line and tumour cell culture
The CD18/HPAF cell line used in the study was originally derived
from the parental heterogeneous HPAF pancreatic tumour cell line
by a limiting dilution technique (Metzgar et al, 1982; Kim et al,
1989). Cells were cultured in Dulbecco’s modified Eagle medium
(DMEM) containing 10% foetal bovine serum (FBS) and penicil-
lin–streptomycin 200Uml
 1 (Life Technologies Inc., Grand
Island, NY, USA). The SW1990 cell line was established from
spleen metastasis of grade II pancreatic adenocarcinoma derived
from the exocrine pancreas (Kyriazis et al, 1983). Cells were
culture in leibovitz’s L-15 medium with 10% FBS and penicillin–
streptomycin 200Uml
 1 (Life Technologies Inc.) at 371C without
CO2. For in vivo injections, cells were harvested from subconfluent
cultures by treatment with 0.05% trypsin and 0.53mM EDTA
(trypsin-EDTA solution; Life Technologies Inc.) and resuspended
in Hank’s balanced salt solution (HBSS) for injection. Only single-
cell suspensions with 490% viability were used for injection.
A portion of tumour tissue, obtained 2 weeks after implantation
of the CD18/HPAF cells into the pancreas or the SC tissue of the
nude mice, was placed in a 10% DMEM medium and minced finely
with a scalpel. The medium containing the tissue pieces was
centrifuged and the supernatant containing the floating fat tissue
was removed. The tissue pellet was treated with DMEM
supplemented with collagenase P (3.75mgml
 1 medium) at 371C
for 15min. The digestion of the tissue was terminated by adding
10% DMEM. After washing the tissue three times in DMEM
medium, tissue fragments were seeded into six-well plates and
incubated at 371C in a humidified atmosphere of 5% CO2 in air.
After 24h, tumour cells began to migrate out from the tissue pieces
into the surrounding areas. The wells became subconfluent at day
5 and were trypsinised with Trypsin-EDTA solution twice for
different time periods: first for 1min to detach and remove the
fibroblasts and second for 5min to harvest the tumour cells. Cells
were washed and seeded in flasks containing 10% DMEM medium.
OT and ectopic implantation of tumour cells
Tumour cells were harvested from the culture flasks by
trypsinisation in EDTA solution, and were washed by centrifuga-
tion in a serum-containing medium. After being washed twice in
PBS pH 7.4 (Life Technologies Inc.), they were resuspended in the
same buffer at a concentration of 10 10
6cellsml
 1. Mice were
anaesthetised with 100–200mgkg
 1 ketamine and 5–16mgkg
 1
of xylazine. A volume of 50ml of cell suspension
(10 10
6cellsml
 1) was injected into different tissues like the
pancreas, submandibular gland (SMG), ovary, stomach, and SC
site. After the injection, the organ was returned to the correct
position and the abdomen was sutured using chromic catgut. The
skin was closed with metal clips, which were removed 10 days later.
The SC injection was performed using 50ml of cell suspension at a
site on the back between the scapulae. After implantation, mice
were inspected twice a week. Tumour formation was checked twice
a week in the first 2 weeks and daily thereafter. Tumour-bearing
mice were killed when an intra-abdominal mass measuring B2cm
in diameter was palpated. To assess the tumour dissemination
pattern, in each group at least four mice were kept alive until they
were moribund. After sacrifice, primary tumours and the
metastatic tumours were weighed, measured, and cut into small
fragments. These fragments were processed for immunohisto-
chemistry (IHC) or RNA isolation, or were kept in tissue culture
medium and processed to obtain a cell line, as described in the
previous section.
Isolation of RNA and Northern blotting
The total cellular RNA from the normal human pancreas, human
pancreatic xenografts, and CD18/HPAF cell line was isolated by the
guanidine isothiocyanate and cesium chloride (CsCl) cushion
ultracentrifugation method (Chirgwin et al, 1979). The Northern
blots were performed as described previously (Choudhury et al,
2000b).
Immunohistochemical examinations
Xenographic tumour tissues were fixed in 10% buffered formalin
and embedded in paraffin. Tumour sections (5mm) were assayed
for MUC4 apomucin by using a modification of the previously
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ydescribed ABC immunohistochemical method (Pour et al, 1993;
Batra et al, 1995). Briefly, tissue sections were deparaffinised in
xylene, rehydrated in graded ethanol, and treated for 20min with
0.3% H2O2/methanol to block endogenous peroxidase. The
sections were blocked with normal goat serum for 1h, followed
by incubation at 41C overnight with either anti-MUC4 rabbit
antiserum raised against 16 amino-acid tandem repeat peptide (Ser
Thr Gly Asp Thr Thr Pro Leu Pro Val Thr Asp Thr Ser Ser Val) or
pre-immune rabbit serum as a negative control. The specificity of
the antisera generated against the tandem-repeat peptide in
staining pancreatic tumour cells was evaluated as described earlier
(Choudhury et al, 2000b).
Semiquantitative reverse transcription–polymerase chain
reaction (RT–PCR)
Total RNA (0.5mg) from the tumour tissue or cell lines was reverse
transcribed using the first-strand cDNA synthesis kit (Perkin-
Elmer, Branchburg, NJ, USA) and oligo d(T) primers, according to
the manufacturer’s instructions. Oligonucleotide primers to the
nontandem repeat region of MUCs 1, 2, 3, 4, 5AC, 5B, 6, 7, TGFb1,
and TGFb2 are designed from the published sequences in the
GenBank, as described earlier (Choudhury et al, 2000b). The
mucin genes and TGFb were coamplified with the same GAPDH
primers. Amplifications were performed in a programmable
thermal controller (PTC-100, MJ Research, Inc., Watertown, MA,
USA). PCR amplification reactions were described previously
(Andrianifahanana et al, 2001; Choudhury et al, 2000b). For
convenience, the corrected densitometric scores for different
products were categorised in three different ranges: high value
(þþþ), moderate value (þþ), and weak value (þ). Each
value was determined as the mean of four densitometry readings.
RESULTS
In vivo tumorigenicity and metastatic behaviour of CD18/
HPAF cells
CD18/HPAF cells were implanted orthotopically (OT) or ectopi-
cally (SC) in nude mice. After 7 days, at any given time point, the
extent of tumour growth was higher at OT compared to SC sites. At
20 days after injection, the OT tumour volume was found to be 2.5-
fold higher as compared to the SC tumours, reflected in the tumour
weight, as shown in Table 1. Among the six mice bearing OT
tumours, two showed extensive invasion of the stomach and
duodenum, and three showed regional invasion of the stomach
and duodenum. Four mice from each group (OT and SC) were
killed after 30 days when they became moribund, and were
dissected to examine the sites of metastasis. Tumours of CD18/
HPAF cells in pancreas (OT tumours) showed a high incidence of
metastases to regional lymph nodes (LNs) and distant metastasis
to mediastinal LNs and mesenteric LNs. In contrast, the SC
tumours were confined to the site of injection and none of the mice
harbouring these tumours showed detectable signs of metastases
(Table 1). None of these tumours (OT or SC) showed any signs of
necrosis.
Similar results were obtained using another pancreatic tumour
cell line, SW1990, where a significant difference in tumour volume
(Po0.01) was observed for the OT tumour 6182þ1003mm
3
compared to SC tumour 1774þ844mm
3. The OT tumours
Table 1 Tumorigenicity and production of spontaneous metastases in CD18/HPAF cells
Injection site
a Latent period
b Tumour volume
c Tumour weight
d Tumorigenicity
e LN metastases
f
SC 1170.64 9807125.53 1.070.42 9/10 0/4
OT 770.40 25527582.97 1.870.52 9/10 4/4
a10 10
6 viable tumour cells were injected into the pancreas or subcutis of two groups of 10 mice/group.
bDays post-injection (7SE), when the tumours could be palpated.
cTumour volume (mm
37s.e.) on day 20 Tumour size was measured with a caliper.
dAverage of the weight (in grams7s.e.) of the tumours isolated from different mice.
eNumber
of mice with tumours/number of injected mice.
fLymph node (LN) metastases include mediastinal lymph node, mesenteric lymph node, iliac lymph node, and inguinal lymph node
metastases.
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Figure 1 Northern blot of total cellular RNA (20mg) separated in a 1%
agarose/formaldehyde gel from the normal human pancreas tissues, CD18/
HPAF cultured cells, and the CD18/HPAF cells grown as SC and OT
tumours. (A) Blot was probed with a
32P-labelled MUC4 tandem repeat
cDNA probe, and the same membrane was stripped and hybridised with a
GAPDH cDNA probe. (B) Densitometric values (7s.e.) for the bands
above in three different experiments were determined by using Molecular
Dynamics ImageQuant software program. Values obtained for the MUC4
smear were divided by the densitometic values for the GAPDH band.
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the SC tumours.
Expression of MUC4 mRNA by OT and SC tumours
We further analysed the status of MUC4 transcripts in the tumours
that are generated in two different host environments. Total RNA
isolated from the tumour cell line (CD18/HPAF), tumour tissues,
and normal human pancreas was fractionated on agarose gel
electrophoresis, Northern blotted, and probed with a MUC4
tandem repeat cDNA probe. As reported in our previous study
(Choudhury et al, 2000b), the MUC4 cDNA probe hybridised to a
large-sized transcript (B26.5kb) in CD18/HPAF cells, and showed
a smear ranging from 10 to 29kb in the OT tumours on Northern
blot (Figure 1). The conceptual expected transcript size of the
MUC4 in HPAF cells will be B26.5kb (Choudhury et al, 2000a).
OT tumours showed an MUC4 transcript similar or little higher
than the parental cell line CD18/HPAF (Figure 1). On the other
hand, MUC4 was not detected in the SC tumour, and the value
showed in Figure 1 is the background. The MUC4 mRNA expression
in normal human pancreas was below the background level.
Histology and MUC4 protein expression in tumours
We studied the tumour histology of the MUC4-expressing OT as
well as the tumours showing undetectable MUC4 expression, and
were interested to see if there is any correlation with the tumour
morphology. Histopathological examination of the tumour tissues
stained with haematoxylin and eosin revealed well-developed duct
formation and cellular polarisation in the OT tumour (Figure 2A).
In contrast, the SC tumour sections showed an amorphous mass of
cells with very little development of ducts in the tumours, and the
cells were anaplastic. The tumour cells lacked cellular polarisation
and, therefore, did not form luminal spaces (Figure 2B).
The MUC4 protein expressions in OT and SC tumour sections
were determined by IHC, using a rabbit polyclonal antiserum
raised against MUC4 (Choudhury et al, 2000b). The immunor-
eactivity of the anti-MUC4 antibody was seen in OT tumour
sections (Figure 3A), but not in SC tumour sections (Figure 3B).
The positive staining in the OT tumour section was specifically
blocked by pre-incubation of the MUC4-antiserum with the
tandem repeat peptide (data not shown). The control sera
(i.e., the pre-immune sera) did not show reactivity with any
tumours. The OT tumours showed metastases to the LNs (Table 1).
The metastasised LN tumours showed morphology and MUC4
staining similar to that observed in the OT tumours (data not shown).
In vitro expression of MUC4 mRNA by OT and SC tumour
cells
To answer the question if there was a clonal expansion of non-
MUC4-expressing cells in the SC tumours (showing undetectable
Figure 2 Tumour of CD18/HPAF cells grown in nude mice. (A)O T
tumour showing a moderately differentiated tumour with glandular
structures filled with mucin. (B) The same cells grown in SC tissue,
showing an amorphous mass of tumour cells with no signs of differentiation.
Original  32.
Figure 3 Immunohistochemical staining of CD18/HPAF cells grown in
the pancreas of the nude mouse (A) and in SC tissues (B). The CD18/
HPAF tumours in the pancreas show immunoreactivity to anti-MUC4
antiserum (1:100 dilution (A)), whereas the pancreatic tissue of the nude
mouse remains unstained, as do the tumours grown in SC tissue (B).
Original  50 (A,B).
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tumours, and studied the MUC4 expression. In SC tumour cells
cultured in vitro, MUC4 mRNA expression appeared gradually and
increased from passage 2 to 6, with an expression level similar to
MUC4 in the CD18/HPAF parental cell line in later passages
(Figure 4). OT tumour cells in culture showed a transient decrease
in the level of MUC4 transcripts and also exhibited a level
comparable to MUC4 in CD18/HPAF (Figure 4) in the later
passages.
TGFb expression in tumour cells, OT and SC tumours
Previously, we demonstrated a positive correlation in the
expression of MUC4 and TGFb2 transcripts (Choudhury et al,
2000b). For this analysis, the expression of TGFb1 and TGFb2 was
studied by RT–PCR using total RNA isolated from CD18/HPAF
cells and OT and SC tumours (Figure 5). We found that OT
tumours showed TGFb2 expression with a range two-fold higher
than the parental cell lines CD18/HPAF. However, the SC tumour
samples showed no undetectable TGFb2 expression. Sometimes, a
very low level of TGFb2 was detected in SC tumours (two out of the
six) without expression of MUC4 (data not shown). On the other
hand, the expression of TGFb1 was found to be similar in tumours
(OT and SC) and the CD18/HPAF cells.
As a control, another cell line, SW1990, was used to validate the
results. The SW1990 line was implanted in OT and SC sites in nude
mice. Expression of MUC4 as well as TGFb2 was investigated. The
SW1990 OT exhibited a high level of MUC4 and TGFb2, as
compared to the SW1990 parental line or the SW1990 SC (data not
shown).
Expression of mucin genes in normal human pancreas,
CD18/HPAF cell line, OT and SC tumours
To obtain a comparative picture of MUC4 expression along with
other mucin genes, RT–PCR amplification was performed using
mucin gene-specific and GAPDH primers designed from the
published sequences in the GenBank. A comparison of mucin gene
expression in the normal human pancreas tissue, pancreatic
tumour cell line (CD18/HPAF), and tumour tissues (OT and SC) is
shown in Table 2. Consistent with the Northern blot and IHC, RT–
PCR showed no expression of MUC4 in the normal human
pancreas and the SC tumours, whereas a high level of MUC4
expression was found in the CD18/HPAF cell line and the OT
tumours. The expression of MUC1 and MUC5B appeared similar in
all the samples. MUC2 was detected only in the tumour cell line,
but not in the normal human pancreas and tumour samples. The
expression of MUC5AC was weak in OT and SC tumours, with
traces in the cell line and normal human pancreas. MUC6 was
detected at a high level only in the normal pancreas. MUC3 and
MUC7 mRNA expression was not detected in the CD18/HPAF cell
line and tumour samples. The positive controls (as mentioned in
the Materials and methods section) for MUC2, MUC3, MUC5AC,
MUC5B, and MUC7 showed mucin expression. Among eight mucin
genes analysed, MUC4 was the only gene that showed high levels of
expression in OT tumours, with no detectable expression in the
normal pancreas or SC tumours. For PCR analysis, primers were
designed in the non-tandem repeat regions of the human mucin
genes. The amplified PCR products for each mucin gene showed
the expected size with 100% sequence identity to the correspond-
ing human sequences, thereby ruling out the possibility of
amplification of the mouse Muc4.
DISCUSSION
The MUC4 mucin exhibits a pancreatic tumour-associated
expression, with no detectable expression in a normal pancreas
(Balague et al, 1994; Hollingsworth et al, 1994; Kim et al, 1999;
Choudhury et al, 2000a; Andrianifahanana et al, 2001). Based upon
the structural information, MUC4 has been proposed to exist as a
heterodimeric molecule consisting of a large mucin-type subunit
and a membrane-anchored subunit with three EGF-like domains
(Moniaux et al, 1999; Choudhury et al, 2000a). It has been
proposed that the MUC4 mucin may have growth factor-like
properties, because its rat homologue (rat Muc4) is referred to
interact with the oncogene p185
neu (Carraway et al, 1999).
Overexpression of SMC (rat Muc4) has been shown to promote
tumour growth in primary tumours and has resulted in metastasis
(Komatsu et al, 2000).
In the present study, the effect of the host local environment on
MUC4 expression was examined in nude mice. The clonal human
pancreatic cancer cell line CD18/HPAF that expresses a high level
of MUC4 mRNA (Choudhury et al, 2000b) was used for generating
human pancreatic xenografts at different sites in nude mice. We
observed significantly higher tumour growth (Po0.01) rates after
implantation at OT sites compared to SC sites in nude mice. In
addition, the OT tumours also showed a high incidence of
metastasis to regional LNs, and distant metastasis to mediastinal
LNs and mesenteric LNs. A high level of MUC4 transcripts and
proteins was observed in the human pancreatic tumour xenografts
at an OT site, a site analogous to human pancreas that does not
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Figure 4 (A) Northern blot of total cellular RNA (20mg) extracted
from SC tumour cells, OT tumour cells at different passages and CD18/
HPAF cell line, separated in a 1% agarose/formaldehyde gel. (a) Probed
with
32P-labelled MUC4 tandem repeat cDNA probe. (b) The same
membrane as shown in (a), probed with a GAPDH cDNA probe. (B)
Densitometric values (7s.e.) for the bands in three different experiments
were determined by using Molecular Dynamics ImageQuant software
program. Values obtained for the MUC4 smear were divided by the
densitometric values for the GAPDH band.
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generated at other MUC4-expressing sites in nude mice like
SMG and stomach, these tumours also showed equivalent
levels of MUC4 (unpublished result). Pancreas, SMG, and
stomach, being physiologically active organs that are well
perfused compared to the SC environment, have spare
vasculature. The MUC4-expressing cells, when grown in the well-
vascularised site (OT), revealed a high level of MUC4 expression,
as compared to a less-vascularised (SC) environment. The
observation suggests a role of serum factors in regulating the
MUC4 expression, or there may be a clonal expansion of a non-
MUC4-expressing cell type in the SC tumours. To answer these
questions, we harvested SC tumour cells and cultured them in
vitro. The in vitro culture of SC tumour cells returned the
expression of MUC4 transcripts to the parental cell line level,
further suggesting a role of serum factor(s) in regulating MUC4
expression. Our earlier study also demonstrates a serum-depen-
dent increase in MUC4 expression in human pancreatic tumour
cells (Choudhury et al, 2000b).
Further, histological examination of the tumours revealed the
OT tumours as moderately differentiated, whereas the SC tumours
were poorly differentiated, suggesting that the expression of MUC4
could be influenced by the differentiation grade of tumours. We
have made similar observations on a panel of pancreatic tumour
cell lines, where a majority of differentiated adenocarcinomas
showed higher levels of MUC4 transcripts compared to cell lines
derived from poorly differentiated adenocarcinomas (Hollings-
worth et al, 1994; Choudhury et al, 2000a; Andrianifahanana et al,
2001).
The lack of detectable expression of MUC4 in SC tumours could
also be due to paracrine regulation from the surrounding tissue
environment that may be blocking the transcription of MUC4.
Paracrine stimulation by growth factors and cytokines has been
demonstrated to be one of the mechanisms responsible for the
organ preference and proliferation of the tumour cells. In the
human colon carcinoma cell line, paracrine stimulation by
a soluble factor from human colon connective tissue was
involved in inducing the expression of the MUC1 mucin in vitro
(Irimura et al, 1990). Cytokine-like tumour necrosis factor-a,
interleukins, and EGF have been shown to be involved in the
regulation of mucin gene expression (Dabbagh et al, 1999;
Longphre et al, 1999; Takeyama et al, 1999; Kim et al, 2000;
Smirnova et al, 2000). One of the cytokines (i.e. TGF-b) showed an
increased expression in many advanced human cancers (Gorsch
et al, 1992; Gold et al, 1994) including pancreatic cancer (Friess
et al, 1993a,b). A TGFb2-dependent increase in MUC4 expression
in pancreatic adenocarcinoma (Choudhury et al, 2000b) and
elevated levels of TGFb2 transcripts in MUC4-expressing OT
tumours suggest the involvement of this cytokine in MUC4
regulation by autocrine and/or paracrine manner in CD18/HPAF
tumours. Nevertheless, the expression of MUC4 is also regulated
by TGFb2, post-translationally and post-transcriptionally in
normal and mammary adenocarcinoma cells, respectively
(Price-Schiavi et al, 1998, 2000).
Earlier studies have shown that the organ environment can
influence tumorigenesis; production of degradative enzymes;
melanin and angiogenic molecules; induction of terminal differ-
entiation; level of P-glycoprotein associated with the multiple
drug-resistance phenotype; and IL-8 expression (Hart and Fidler,
1980; Price et al, 1988; Nakajima et al, 1990; Staroselsky et al, 1990;
Fabra et al, 1992; Wilmanns et al, 1992; Radinsky et al, 1994;
Gutman et al, 1995). The influence of the organ environment on
the growth of tumour cells was originally proposed in Paget’s
hypothesis of the ‘seed and the soil’ (Paget, 1989).
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Figure 5 (A) Analysis of TGFb1 and TGFb2 expression in CD18/HPAF
cells, OT tumours, and SC tumours. Total RNA was isolated; TGFb and
GAPDH mRNA are coamplified in each reaction by RT–PCR. (B) The band
intensity of the amplified products was quantified for each sample using the
gel expertt 3.5 software suite. The densitometric values (7s.e.) for the
bands in three different experiments were calculated for a gene-specific
product and GAPDH for each reaction. The value for a gene-specific
product is expressed per unit of GAPDH to account for any differences in
the starting amounts of RNA. OT, orthotopic tumour; SC, subcutaneous
tumour; S, serum; SF, serum-free.
Table 2 RT–PCR expression analysis of mucin genes expression
Sample MUC1 MUC2 MUC3 MUC4 MUC5AC MUC5B MUC6 MUC7
CD18/HPAF +++ +   +++ +/  ++   
OT tumour +++    +++ + ++   
SC tumour +++     ++ + + /   
Pancreas ++     +/  ++ ++  
Three orthotopic (OT), three subcutaneous (SC), and seven normal human pancreas were analysed. +++, high; ++, moderate; +, low;  , undetectable; ND, not determined.
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vivo regulation of human MUC4 expression in pancreatic tumours.
The expression of MUC4 was high in moderately differentiated
tumours, with undetectable levels in poorly differentiated SC
tumours. The OT tumours also showed metastases not only to the
regional but also to the distant LNs. The SC tumour cells, when
cultured in vitro, showed MUC4 expression, suggesting a role of
serum factor(s) in its regulation. Our results also indicated a direct
correlation between the MUC4 expression and the levels of TGFb2
transcripts in the CD18/HPAF tumours, as well as in CD18/HPAF
cells in vitro, as described earlier (Choudhury et al, 2000b). These
results reveal that the local host environment regulates the MUC4
expression in pancreatic tumours (CD18/HPAF) under in vivo
conditions.
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